NCT06962787 2025-11-17A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal CancerSichuan Baili Pharmaceutical Co., Ltd.Phase 2 Recruiting260 enrolled